Search

Displaying results 7081 - 7090 of 10000 in total
  1. Drug

    Raludotatug deruxtecan

    go.drugbank.com/drugs/DB19447
    Investigational

    Raludotatug deruxtecan is under investigation in clinical trial NCT06660654 (A Study of Raludotatug Deruxtecan in Participants With Advanced/metastatic Solid Tumors (Rejoice-pantumor01)).

    Synonyms: R-DXd, immunoglobulin G1-kappa, anti-[Homo sapiens CDH6(cadherin 6, K-cadherin (foetal kidney), cadherin 6 type 2)], humanized monoclonal antibody conjugated to deruxtecan, comprising a linker and a camptothecin
  2. Drug

    Dorocubicel

    go.drugbank.com/drugs/DB19448
    Approved

    [L54106] Dorocubicel, as a component of Zemcelpro, was granted conditional marketing authorization in the European Union in August 2025 for use in allogeneic hematopoietic stem cell transplantation … following myeloablative conditioning in adult patients for whom a suitable donor is not available.

  3. Drug

    TDI-01

    go.drugbank.com/drugs/DB19450
    Investigational

    TDI-01 is a small molecule is being developed by Beijing Tide Pharmaceutical.

  4. Drug

    MIP-1095 I-131

    go.drugbank.com/drugs/DB14978
    Investigational

    MIP-1095 I-131 is under investigation in clinical trial NCT03030885 (Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)).

  5. Drug

    Martinostat

    go.drugbank.com/drugs/DB14979
    Investigational

    Martinostat is under investigation in clinical trial NCT03721211 (Imaging With [11C]Martinostat in Breast Cancer).

  6. Drug

    Nomacopan

    go.drugbank.com/drugs/DB14991
    Investigational

    Nomacopan is under investigation in clinical trial NCT03427060 (Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms).

    Categories: Recombinant Protein Inhibitor of Complement Factor 5
  7. Drug

    Pegunigalsidase alfa

    go.drugbank.com/drugs/DB14992
    ApprovedInvestigational

    Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized … [A259347,A259352] In May 2023, the EMA granted marketing authorization to pegunigalsidase alfa in the European Union (EU) for the treatment of adult patients with Fabry disease.

  8. Drug

    Pateclizumab

    go.drugbank.com/drugs/DB14997
    Investigational

    Pateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared … With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis).

  9. Drug

    Human interferon beta

    go.drugbank.com/drugs/DB14999
    ApprovedInvestigational

    [A191784] Interferon beta is currently being studied as a possible treatment for COVID-19, which results from infection with the novel 2019 SARS-CoV-2 virus. … It is therefore a potential drug candidate for SARS-CoV-2 based on viral genetic similarity.[A191733,L12012]

    Categories: Interferon Type I
  10. Drug

    Dianexin

    go.drugbank.com/drugs/DB15000
    Investigational

    Dianexin is under investigation in clinical trial NCT00615966 (Phase 2 Study of the Safety of Diannexin in Kidney Transplant Recipients).